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Since Anthony van Leeuwenhoek, first microscopic observations of
the unseen microbiota and the more recent realization that little of
the microbes in the biosphere are known, humans have developed
a deep curiosity to fully understand the inner workings of the microbial realm. Our ability to characterize the complexity of microbial
communities in their natural habitats has dramatically improved over
the past decade thanks to advances in high-throughput methodologies. By eliminating the need to isolate and culture individual species,
metagenomics approaches have removed many of the obstacles that
hindered research in the ecology of mixed microbial consortia, providing valuable information about the diversity, composition, function, and metabolic capability of the community.
Microbes are the unseen majority with the capability to colonize every environment, including our bodies. The establishment and composition of a stable human microbiome is determined by the host
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Fig. 1. Microbiome of modern humans is influenced by life-style choices. During everyday life, humans are exposed to many external and internal environmental factors that can influence the composition of their microbiome. The human microbiome is here represented by the microbiota of the skin, mouth, and gut, and next to
each body site a series of environmental modifiers. Some of these modifiers, such as
general health, diet, medications, and stress, can affect the microbiota of more than
one body site, but others, such as toothbrush and toothpaste, can directly modify
the microbiota of only one body site.

genetics, immunocompetence, and life-style choices. Our life-style
choices determine our exposure to many external and internal environmental factors that permanently or temporarily can influence
our microbiome composition. Figure 1 illustrates some of the lifestyle-related factors that might influence the microbiota of the skin,
mouth, and gut. It is not limited to what we carry, touch, breath, and
eat. Other dispersal vectors include secretion, excretions, aerosols, air
flow, animals, moving surfaces, water, beverages, food, contact, wind,
tools, toiletry, and others. These influence the microbiome membership, who are present, and they have the ability to participate in the
microbiome dynamic within an environment. The establishment of a
microbial community is dependent on many environmental factors,
including pH, temperature, altitude, weather, soil type, nutrient availability, relative humidity, air quality, pollutants, microbial competitors,
and others. In other words, we are superorganisms interconnected
with other living forms on this Earth.
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The exploration of the microbial worlds uncovered the extreme mi
crobial diversity throughout the biosphere, from hydrothermal vents
on the ocean floor to the intestinal tract of animals. In addition to
metagenomics, other technologies including metatranscriptomics,
metaproteomics, metabolomics, and metalipidomics can provide better insights of the microbial ecosystems dynamics. Fundamental gaps
in knowledge still exist. We will take few examples to discuss the
promises of the upcoming discoveries.
Microbiome During Development and Disease
Since the 1980s, advances in sequencing technologies have uncovered the immense diversity and functional capabilities of the microbial
world. More recently, the introduction of next-generation sequencing
(NGS) combined with metagenomics approaches has allowed a better
understanding of the complexity of the interactions between animals
and their associated microbiota, in particular, the gut microbiome.
The digestive tract of animals has coevolved with a diverse and
complex microbial community that responds to host diet and provides metabolic signals to the host during its developmental stages
among many other functions.1 The permeability of the gut facilitates
the transport of metabolites produced by the microbiota, which allows
the signaling and interactions between the gut microbiota and the
host organs and tissues.2 Host immune and nervous system as well as
behavior including mating can be influenced.1,3,4 The use of metagenomics approaches to understand the complex metabolic interactions
between the human host and its microbiome has revealed extensive
variability in the diversity and composition of the microbiome between
individuals and throughout the life-span of the host. A representation
of this knowledge is summarized in Figure 2. Our growing knowledge
of the magnitude and complexity of the interactions between the host
and the gut microbiome is drastically changing our views of human
health, disease, and aging.2 The lifelong changes in the complexity of
the host–microbiome metabolic interactions offer the opportunity for
the development of specific therapeutic interventions targeting the
gut microbiome throughout the life-span of the host.
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Fig. 2. Gut microbiota in development and disease. The influence of the gut microbiota on human health is continuous from birth to old age. The maternal microbiota may influence both the intrauterine environment and the postnatal health
of the fetus. At birth, about 100 microbial species populate the colon. Early environmental factors (e.g., method of delivery), nutritional factors (e.g., breastfeeding
or bottle feeding), and epigenetic factors have been implicated in the development of a healthy gut and its microbial symbionts. Changes in gut microbial composition in early life can influence risk for developing disease later in life. During
suckling, the microbial community develops rapidly; shifts in microbial diversity
occur throughout childhood and adult life, and in old age, there is a decrease in
the Bacteroidetes and an increase in the Firmicutes species. The gut microbiota is
important for maintaining normal physiology and energy production throughout
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Therapeutic Potential of Microbiota Modifications
Metagenomic studies have uncovered the connections between
the disease and the changes in the homeostasis of host–microbiota
interactions.2 Such findings have renewed the interest of the medical
community toward therapeutic interventions targeting the gut microbiota. Although unknowingly, humans have performed microbial
modification for hundreds of years, the first deliberate use of microbial modification for human health date from the beginning of the
last century.5,6 In 1907, Ellie Metchnioff suggested that the consumption of lactic acid bacteria could improve health and longevity, and
initiated the modern probiotics movement. Probiotics are “live microorganisms that, when administered in adequate amounts, confer
a health benefit on the host.”5,6 Although the application of comparative genomics approaches have contributed to elucidate the genetic
components that confer probiotic properties to certain taxa, metagenomics methodology allows more comprehensive studies of the effect
of probiotics.5,7 Metagenomics together with other omics approaches
can potentially identify the metabolites and metabolic pathways inducing the host–microbiota feedback mechanism by which probiotics can modulate health.
Extensive multi-omics studies are needed to fully understand how
changes in the ecology of the gut microbiota relate to disease and
how to better design and utilize microbial modification therapies.8
Which are the microbiome structural and homeostatic changes associated with the development of secondary infections following the

life. Body temperature regulation, reproduction, and tissue growth are energydependent processes that may rely in part on gut microbial energy production.
Extrinsic environmental factors (such as antibiotic use, diet, stress, disease, and
injury) and the mammalian host genome continually influence the diversity and
function of the gut microbiota with implications for human health. Disruption of
the gut microbiota (dysbiosis) can lead to a variety of different diseases, including (A) inflammatory bowel disease, colon cancer, and irritable bowel syndrome;
(B) gastric ulcers, nonalcoholic fatty liver disease, and obesity and metabolic syndromes; (C) asthma, atopy, and hypertension; and (D) mood and behavior through
hormone signaling. The gut microbiota is also important for drug metabolism and
preventing the establishment of pathogenic microbes. (Reprinted with permission
2
from the American Association for the Advancement of Science. )
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administration of broad-spectrum antimicrobials?9 How are the homeostasis and ecological dynamics of the host-microbiome interactions affected by the elimination of specific taxa after immunization?
Microbiota modification will soon fall into the realm of personalized
and preventive medicine.10–13
So far, the best evidence of the therapeutic potential of microbiota
modifications is fecal microbiota transplantation (FMT). The replace
ment of the patient’s gut microbiome with the microbiome from a
healthy donor has been very successful in the treatment of antibiotic-resistant Clostridium difficile infections. More in-depth metagenomics studies from patients with C. difficile infections before and
after fecal transplants are needed to determine if it is possible to obtain the same therapeutic benefits by introducing selected members
of the microbial community or if indeed the full replacement of the
gut microbiome is needed.14,15 The efficacy of therapeutic interventions based on microbiota modulation will have to be demonstrated
by their ability to consistently restore a healthy steady state. The success of the first randomized clinical trial demonstrating the effectiveness of the FMT for the treatment of recurrent C. difficile infections
has catalyzed the formation of FMT-patient advocacy groups, and the
establishment of stools banks to ultimately encourage the development of targeted therapies.14,16,17 The success of FMT suggests that it
might be appropriate to establish strict regulations for the screening
of infectious disease in microbiome transplants, similar to the ones in
place for organ transplants.14,16,17
Challenges Ahead: Human Microbiome Information in the
Health Care System
In November 2013, the US Food and Drug Administration (FDA) approved the marketing of the NGS systems as diagnostic devices for
human genome sequencing.18,19 The authorization by the FDA of the
Illumina sequencing platform for whole human genome surveys in the
clinical setting paves the way for the development of new sequencing-based clinical tests, potentially including microbiome profiling. It
is predicted that in the future, the patient genome and microbiome
data can be integrated allowing the identification of medically relevant variants that might transform clinical research and patient care.
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Potentially, these combined data sets can help inform about disease
predisposition or responses to drugs allowing the design of personalized care and/or early therapeutic interventions. Many challenges
need to be conquered before microbiome information is routinely incorporated in health care.
Extensive studies of microbiome profile variations among healthy
individuals are needed before microbiome data can be used for predicting disease predisposition, onset, and progression, and drug–response modulation. Similar to the human genome sequencing, the
full integration of microbiome data in the clinical setting requires major research efforts in the collection of rigorous evidence supporting
the role of the microbiome in health and disease, the development of
appropriate regulatory and validation policies, the implementation of
policies addressing patients’ rights, and the training of the physician
and health care professionals in microbiome data interpretation.20 A
lot of research and validation will be required before the approval by
the FDA of microbiome profiling in the clinical setting. Accuracy, precision, analytical sensitivity and specificity, reference range, and reportable range will be scrutinized. In the United States, the Clinical Laboratory Improvement Amendments (CLIA), which perform testing of
clinical laboratories to ensure their accuracy in testing human samples, will have to develop new standards that can capture the microbiome complexity. As many other technological advances and discoveries, there is likely to be a lapse of time before the actual adoption
of the new technology into the clinical setting.
Ethical Considerations of Microbiome Research
In the 21st century, the Internet and other digital technologies have
facilitated the access to personal information raising concerns related to privacy and data rights issues. The ease of the data accessibility has serious implications for the regulation of research in human
subjects. In microbiome research, those regulatory issues are related
to the selection and recruitment of human subjects, the possibility of
individual or group stigma associated with the research findings, privacy and confidentiality, and informational risks associated with disclosure of some of the findings.21–25 Additionally, microbiome research
subjects may be identified by the disclosure of information collected
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from the behaviors survey and/or from the microbiota samples. In addition to the issues related to research-generated data, unique to the
human microbiome are issues related to informed consent for future
use of stored microbiota samples.26–28 “Who owns your poop?” is the
humorous and thought-provoking question posed by Alice Hawkins
and Kieran O’Doherty, while discussing the impact on microbiome research of issues related to privacy, consent, ownership, return of results, governance, and benefit sharing.28 Although some ethical issues
are unique to microbiome research, similar ethical concerns were extensively debated during the Human Genome Project and, more recently, genome-wide association studies.24,29
To better address the ethical issues facing contemporary research
such as microbiome research, in 2011, the US Department of Health
and Human Services issued an Advance Notice of Proposed Rulemaking (ANPRM), entitled “Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay,
and Ambiguity for Investigators,” proposing changes to the “Common Rule,” as the current federal policy for the Protection of Human
Subjects is known.43 Some of the ANPRM proposed changes include:
(1) adjusting Institutional Review Board (IRB) review to contemporary
research, (2) establishing a single IRB review for multi-institution research, (3) specific written consent for the use of biospecimens, (4)
standards for data security and protection of identifiable or potentially
identifiable data, (5) implementing a systematic approach to the collection and analysis of data on unanticipated problems and adverse
events, and (6) extending the federal rules to apply to all research, regardless of funding source, that is conducted at US institutions that
receive some funding from a Common Rule agency for research using
human subjects. The proposed revisions to the Common Rule present
many challenges to the regulation of research using human subjects
deserving immediate attention by the research community.30
The ethical issues facing microbiome research require the
implementation of novel guidelines on the proper and ethical collection and use of the data generated by this technology. At the same
time, to stimulate and facilitate the process of discovery and to keep
pace with the latest technological advances, it is imperative for the
regulatory agencies to implement a more agile and adaptable evaluation system.
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The artist, like the scientist, can expose and highlight the ethical
and privacy issues associated with new technologies. To raise awareness of our increasing access to biotechnologies, Gabriel Barcia-Colombo created the art installation ‘DNA vending machine’.31 The installation shows visuals of individuals whom donated mouthwash from
which DNA was extracted, as well as a packaged vial of that DNA. The
installation is both troubling and natural. Both oral microbiome and
human DNA should be present in the beautifully condensed genetic
information presented by the artist. One can just wonder how such
material can be used, and if we should expect prepackaged microbiomes to be on the supermarket shelves.
Another side of this ethics debate is whether the microbiota has
rights. Under the assumption “for the benefit of all,” we have the technological capacity to permanently eradiate members of the microbiota or, through synthetic biology, “create new microbiota.”32–34
Citizen Scientist, Crowdsourced Research, and the Microbiome
The increasing evidence suggesting the important role played by the
microbiota in development, aging, and many human diseases has spur
great interest from the general public and has introduced the micro
biome field to the citizen science movement.35–37 Using the citizen sci
ence principles of crowdsourcing and crowdfunding, companies and
open-sourced projects have been established to collect microbiome
samples from donors and provide them with a snapshot of their own
microbiome profile in exchange for a monetary contribution.33 Some
large projects include the American Gut in association with the Human
Food Project and several universities, the Home Microbiome study with
the Alfred P. Sloan Foundation and Argonne National Laboratories, and
the Project MERCCURI to analyze the space station microbiome. Online resources, such as SciStarter and microBEnet, allow the identification of active studies where individuals can be involved. The popularity and success of these types of projects is attributed to the need
of the general public to access scientific information that can potentially impact their lives and health. This need of information is strongly
felt in the case of the gut microbiome, as changes in the gut microbiota have been associated with several debilitating human conditions.
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The citizen science movement can empower the individuals but
at the same time raises several ethical issues and imposes additional
responsibilities and concerns to the researchers involved in such projects.35,38–41 The research community needs to be aware of the implicit
expectations of the citizen scientists and making sure that data collection is not the only goal of the project. While moderating the high
expectations of the citizen scientist, the researchers need to ensure
the proper use of the collected data to help improve the health and
knowledge of, for example, the human subjects.42 Properly used and
integrated with other health status data, the generated microbiome
profiles can potentially provide information very useful to both the human subjects and the research community. If rigorous studies corroborate the observed associations between disease state and changes
in microbiome structure, the information could improve preventive
health care and lead to earlier medical interventions.
Although of immense benefit to the research community and to the
participants, the modality of data collection by citizen scientist presents serious concerns with privacy and security of the data. Microbiome samples contain not only the individuals’ microbiome but also
the genetic information that could potentially identify the sample donor. A successful microbiome citizen science project requires the implementation of the best practices for collection, management, security, analysis, and communication of all the data collected.21–24 It is
important to point out the well-known fact that research conducted
using data collected from self-selected participants have methodological limitations. Because of selection bias, information bias, and
confounding effects, the findings of research using self-selected participants requires cautious interpretation.40 It requires the implementation of the proper analytical methodology to identify and possibly
compensate for those biases and confounding effects.40 This type of
collection efforts require the full awareness of the participants that
the observed correlation or associations might lack accuracy or generality because of those methodological limitations.
The use of self-selected participants can potentially restrict the
health benefits of microbiome profiling to a small sector of the population, because the data collected is skewed based on socioeconomics,
ethnicity, and/or disease state of the donor. Given the current funding situation, it can also limit the testing of alternate hypotheses.35–41
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These data-gathering efforts will facilitate the collection of large number of samples and help the democratization of science by empowering the citizen scientist.
Metagenomics, Agriculture, and Food Microbiology
For living entities, proper nutrition is a key factor for survival. Agri
culture and food microbiology can benefit from metagenomics
advances by improving food safety and security, improving the detection of threats to food production and supply, and increasing the
productivity of domestic animals and plants. In meat production, the
ongoing use of direct-fed microbial could also be optimized in function of the food intake and the animal of choice.
The World Health Organization estimates that worldwide, approxi
mately 2.2 million annual deaths are associated with foodborne and
waterborne pathogens, including bacteria, viruses, and parasites.43
Food and water safety is a worldwide necessity. The depth and high
coverage of NGS makes metagenomics a powerful tool in the detection and surveillance of foodborne pathogens, the detection of outbreaks and transmission routes of foodborne diseases, the testing of
foods and food-associated environments, and the identification of microbiota that may protect against foodborne illnesses.
Although the use of metagenomics approaches to test foods for
the presence of specific foodborne pathogens can be problematic,
its application successfully identified the presence of serovars of Salmonella in samples that tested negative by bacteriological analytical
manual methods and real-time polymerase chain reaction.43,44 In order to facilitate the use of metagenomics by governmental agencies
and the food industry, it is crucial to develop bioinformatics tools tailored to the needs of the food microbiology laboratory and to put in
place the appropriate legal and ethical framework for the collection
and use of the data generated. The use of metagenomics approaches
in the food industry, to better understand, the food-associated microbial communities, can lead to improvements in productivity, quality, and safety of food.43,45
Eliminating hunger worldwide, providing desirable food to a larger
population, and producing the needed food in a sustainable way are
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major challenges facing future food security.46,47 A possible strategy
for meeting those challenges in a sustainable way is to increase agricultural yields and production limits by manipulating above–belowground plant interactions with the goal of reducing pests and increasing crop growth. The association between plants and belowground
soil-borne microbiota increases plant fitness. Plant growth promoting rhizobacteria (PGPR) are able to influence plant growth and increase plant resistance to herbivores and pathogens.47–49 Metagenomics approaches to uncover the interactions between plants and
belowground microbiota in agricultural systems are essential to tailor and target these interactions for maximum benefit to the crops.
More in-depth research in the composition and function of the rhizosphere microbiome is needed in order to better understand and identify the activity of PGPR bacteria in different crops. The knowledge
obtained by the analyses of rhizosphere microbiome can be used to
design PGPR-based interventions that promote plant growth, nutrition, and defense against pests in agricultural systems. The inoculation of soils with beneficial bacteria such as PGPR could be a sustainable approach to increase productions of crops without the input of
chemical fertilizers. Also, soil microbiota manipulation can be poten
tially used to increase nitrogen fixation and reduce the use of fertilizers and subsequent nitrogenization resulting in economical and ecological benefits.50,51
Summary
In this overview, we have highlighted some of the promises and pros
pects of the utilization of omics approaches to the study of microbiomes. Clearly, there is still much work ahead before achieving a
comprehensive understanding of the complex dynamics and interactions within the human microbiome and other microbial ecosystems.
At this time, microbiome research is moving beyond the identification of genes and/or taxa and toward an emphasis on the application of multi-meta-omics technologies with the goal of sorting out the
functions and pathways responsible for the multidirectional interactions between the microbiota, the host, and the environment. A comprehensive understanding of these interactions will contribute to the
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design of more effective, preventive, and therapeutic interventions.
It creates opportunities for a new vision of health and disease treatment that was not imagined in the 20th century.
Many of the resources and technologies required to fulfil the prom
ise of the microbiome are already available. The development of novel
bioinformatics frameworks and analytical techniques are essential in
order to more efficiently mine and synthesize the information of the
so-called “Big Data” embedded in the present research or soon to be
generated.
It is interesting to note the concept of scale involved. From the interaction at the atomic scale of the enzyme and its substrate, driv
ing, in part, the functional assembly of a microbiome, to the dynamic
interactions of biomes, we have moved from the nanometer to the
meter range and beyond. Let’s be ready to stretch our minds a little further and create the tools to better handle the rising concepts.
This methodological and conceptual revolution has provided the
magnification lens needed to better understand the unseen world in
front of our eyes, the microbial communities inhabiting this planet for
over 3.5 billion years. It is a scientific revolution that will soon reach
every citizen.
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